The mosquito-borne disease is sweeping through a province in southern China, which is taking strict measures to quash the outbreak.

The FDA has lifted its previously recommended pause on the use of the Chikungunya virus vaccine in individuals 60 and older, following a benefit-risk assessment. The agency also approved updated ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...

Mosquito-borne chikungunya virus has caused an outbreak in China, but public health experts say the risk for spread and infection in U.S. remains low.

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and ...